Antihypertensive Therapeutics Market Size, Share, Growth & Analysis Report 2020: Radiant Insights, Inc
GBI Research, the leading business intelligence provider, has released its latest research, ''Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries'', which provides in-depth analysis of hypertension therapeutics market within the eight major geographies of the US, the top five European countries (the UK, France, Germany, Spain and Italy), Japan and Canada. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. Browse Full Report With TOC @ http://www.radiantinsights.com/research/antihypertensive-therapeutics-in-major-developed-markets-to-2020-increased-uptake-of-combination-therapies-to-offset-effects-of-key-patent-expiries The value of the hypertension market in the major developed markets amounted to an estimated $40.0 billion in 2013 and is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter. The initial growth will be due to the increased penetration of fixed-dose combination drugs (Amturnide, Exforge Tribenzor, Azor, Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in the prevalence population from 181 million to 190 million at a CAGR of 0.6%, and two new expected launches in the pipeline (azilsartan + amlodipine, and AHU377+ valsartan). However, due to the expiry of the exclusivity of major drugs both before and during the forecast period (Cozaar in 2010; Diovan, Avapro and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna and Tekturna HCT in 2018), increased generic penetration and a low diagnosis rate, the market will decline from 2017.
GBI Research, the leading business intelligence provider, has released its latest research, ''Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries'', which provides in-depth analysis of hypertension therapeutics market within the eight major geographies of the US, the top five European countries (the UK, France, Germany, Spain and Italy), Japan and Canada. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.
Browse Full Report With TOC @ http://www.radiantinsights.com/research/antihypertensive-therapeutics-in-major-developed-markets-to-2020-increased-uptake-of-combination-therapies-to-offset-effects-of-key-patent-expiries
The value of the hypertension market in the major developed markets amounted to an estimated $40.0 billion in 2013 and is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter. The initial growth will be due to the increased penetration of fixed-dose combination drugs (Amturnide, Exforge Tribenzor, Azor, Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in the prevalence population from 181 million to 190 million at a CAGR of 0.6%, and two new expected launches in the pipeline (azilsartan + amlodipine, and AHU377+ valsartan). However, due to the expiry of the exclusivity of major drugs both before and during the forecast period (Cozaar in 2010; Diovan, Avapro and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna and Tekturna HCT in 2018), increased generic penetration and a low diagnosis rate, the market will decline from 2017.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
7.5.6 Pipeline <strong>Analysis</strong> 91<br />
7.6 Expert Panel Validation 91<br />
7.7 Contact Us 91<br />
7.8 Disclaimer 91<br />
List of Tables<br />
Table 1: Anti-Hypertensives <strong>Market</strong>, Possible Co-Morbidities 10<br />
Table 2: Anti-Hypertensives <strong>Market</strong>, Blood Pressure Classification in Adults 12<br />
Table 3: Anti-Hypertensives <strong>Market</strong>, Prevalence Rate (%) 14<br />
Table 4: Anti-Hypertensives <strong>Market</strong>, Initiation of Treatment 15<br />
Table 5: Anti-Hypertensives <strong>Market</strong>, Lifestyle Management 16<br />
Table 6: Anti-Hypertensives <strong>Market</strong>, Major Developed <strong>Market</strong>, Forecast Data, 2013-<strong>2020</strong> 60<br />
Table 7: Anti-Hypertensives <strong>Market</strong>, US, Forecast Data, 2013-<strong>2020</strong> 60<br />
Table 8: Anti-Hypertensives <strong>Market</strong>, UK, Forecast Data, 2013-<strong>2020</strong> 61<br />
Browse Full <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/antihypertensivetherapeutics-in-major-developed-markets-to-<strong>2020</strong>-increased-uptake-of-combination-therapies-tooffset-effects-of-key-patent-expiries<br />
Table 9: Anti-Hypertensives <strong>Market</strong>, France, Forecast Data, 2013-<strong>2020</strong> 61<br />
Table 10: Anti-Hypertensives <strong>Market</strong>, Germany, Forecast Data, 2013-<strong>2020</strong> 61<br />
Table 11: Anti-Hypertensives <strong>Market</strong>, Italy, Forecast Data, 2013-<strong>2020</strong> 62<br />
Table 12: Anti-Hypertensives <strong>Market</strong>, Spain, Forecast Data, 2013-<strong>2020</strong> 62<br />
Table 13: Anti-Hypertensives <strong>Market</strong>, Japan, Forecast Data, 2013-<strong>2020</strong> 62<br />
Table 14: Anti-Hypertensives <strong>Market</strong>, Canada, Forecast Data, 2013-<strong>2020</strong> 63<br />
Table 15: Anti-Hypertensives <strong>Market</strong>, Global, Developmental Pipeline, Discovery Phase 63<br />
Table 16: Anti-Hypertensives <strong>Market</strong>, Global, Developmental Pipeline, Preclinical Phase 64<br />
Table 17: Anti-Hypertensives <strong>Market</strong>, Global, Developmental Pipeline, Phase I 66<br />
Table 18: Anti-Hypertensives <strong>Market</strong>, Developmental Pipeline, Phase II 74<br />
Table 19: Anti-Hypertensives <strong>Market</strong>, Developmental Pipeline Phase III, 2013 77
Change language